A provision in the Inflation Reduction Act of 2022 cuts reimbursements for certain Medicare Part B drugs from the average sales price plus 6 percent to the maximum fair price that is negotiated by CMS. Reimbursement for Part B drugs is expected to be cut by an estimated 50 percent or more for drugs subject to negotiation, according to a Sept. 13 release.
The Protecting Patient Access to Cancer and Complex Therapies Act would maintain current reimbursements to providers for physician-administered drugs, saving Medicare the same amount of money by replacing the average sale price payment cut for Part B drugs with a manufacturer rebate.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
